Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1994 1
1996 1
1997 1
2005 1
2006 1
2007 1
2008 1
2009 1
2014 3
2015 1
2016 2
2017 4
2018 3
2019 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %, %
The following terms were not found in PubMed: 22Protease, 2Fadministration, 5BMeSH
Page 1
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle BA. Chai-Adisaksopha C, et al. Cochrane Database Syst Rev. 2017 Sep 25;9(9):CD011441. doi: 10.1002/14651858.CD011441.pub2. Cochrane Database Syst Rev. 2017. PMID: 28944952 Free PMC article. Review.
The meta-analysis did not conclusively demonstrate significant benefit of prophylaxis on health-related quality of life as measured by Haem-A-QoL score, EQ-5D total score and utility score, EQ-5D VAS and SF-36 physical summary and mental summary score (low quality e …
The meta-analysis did not conclusively demonstrate significant benefit of prophylaxis on health-related quality of life as measured by Haem- …
Toxicology of mono-, di-, and triethanolamine.
Knaak JB, Leung HW, Stott WT, Busch J, Bilsky J. Knaak JB, et al. Rev Environ Contam Toxicol. 1997;149:1-86. doi: 10.1007/978-1-4612-2272-9_1. Rev Environ Contam Toxicol. 1997. PMID: 8956558 Review.
The dual function groups, amino and hydroxyl, make them useful in cutting fluids and as intermediates in the production of surfactants, soaps, salts, corrosion control inhibitors, and in pharmaceutical and miscellaneous applications. In 1995, the annual U.S. production cap …
The dual function groups, amino and hydroxyl, make them useful in cutting fluids and as intermediates in the production of surfactants, soap …
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H, Walder L, Fisher M. Guy H, et al. Pharmacoeconomics. 2019 Mar;37(3):391-405. doi: 10.1007/s40273-018-0745-z. Pharmacoeconomics. 2019. PMID: 30478649 Free PMC article.
Costs included: drug, chemotherapy, monitoring, adverse events, and terminal care. EQ-5D utilities were estimated from trial data. RESULTS: Compared to RS, niraparib was associated with an incremental cost-effectiveness ratio (ICER) of US$68,287/QALY and US$108,287/QALY fo …
Costs included: drug, chemotherapy, monitoring, adverse events, and terminal care. EQ-5D utilities were estimated from trial data. RE …
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. Mantovani G, et al. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1030-4. doi: 10.1158/1055-9965.EPI-05-0538. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16702388 Clinical Trial.
As for quality of life evaluation, there was a marked improvement in the European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5D(VAS), and multidimensional fatigue symptom inventory-short form scores. At the end of the study, 22 of the 39 pati …
As for quality of life evaluation, there was a marked improvement in the European Organization for Research and Treatment of Cancer QLQ-C30, …
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.
Pasquau J, Hidalgo-Tenorio C, Montes ML, Romero-Palacios A, Vergas J, Sanjoaquín I, Hernández-Quero J, Aguirrebengoa K, Orihuela F, Imaz A, Ríos-Villegas MJ, Flores J, Fariñas MC, Vázquez P, Galindo MJ, García-Mercé I, Lozano F, de Los Santos I, de Jesus SE, García-Vallecillos C; QoLKAMON STUDY GROUP. Pasquau J, et al. PLoS One. 2018 Apr 12;13(4):e0195068. doi: 10.1371/journal.pone.0195068. eCollection 2018. PLoS One. 2018. PMID: 29649309 Free PMC article. Clinical Trial.
The primary endpoint was change in patient-reported outcomes in quality of life as measured by the MOS-HIV and EQ-5D questionnaires. Secondary endpoints included treatment adherence, patient satisfaction, incidence of adverse events and differences in plasma HIV-1 RNA vira …
The primary endpoint was change in patient-reported outcomes in quality of life as measured by the MOS-HIV and EQ-5D questionnaires. …
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP Jr, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA. Garrison LP Jr, et al. Value Health. 2019 Apr;22(4):408-415. doi: 10.1016/j.jval.2018.11.014. Epub 2019 Mar 11. Value Health. 2019. PMID: 30975391
We parameterized the model using data from both arms in APHINITY extrapolated to a patient's lifetime horizon. Estimates of health state utilities were based on EQ-5D trial data and the literature, and costs were estimated from government sources and the published literatu …
We parameterized the model using data from both arms in APHINITY extrapolated to a patient's lifetime horizon. Estimates of health state uti …
Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
Kawata AK, Lenderking WR, Eseyin OR, Kerstein D, Huang J, Huang H, Zhang P, Lin HM. Kawata AK, et al. J Med Econ. 2019 Sep;22(9):924-935. doi: 10.1080/13696998.2019.1624080. Epub 2019 Jun 25. J Med Econ. 2019. PMID: 31125274 Free article. Clinical Trial.
QLQ-C30 scores were mapped to European Quality-of-Life-5 Dimensions (EQ-5D) utility scores using two published algorithms (Khan et al. for EQ-5D-5L; Longworth et al. for EQ-5D-3L). ...
QLQ-C30 scores were mapped to European Quality-of-Life-5 Dimensions (EQ-5D) utility scores using two published algorithms (Khan et al …
US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?
Huang IC, Willke RJ, Atkinson MJ, Lenderking WR, Frangakis C, Wu AW. Huang IC, et al. Qual Life Res. 2007 Aug;16(6):1065-72. doi: 10.1007/s11136-007-9206-4. Epub 2007 Apr 6. Qual Life Res. 2007. PMID: 17415683 Clinical Trial.
The correlation coefficient for EQ-5D utilities using the US and UK weights was 0.98. The correlations of EQ-5D index scores with the MOS-HIV scores were moderate and similar using the US and UK weights. ...The changes in EQ-5D index scores from baseline to w …
The correlation coefficient for EQ-5D utilities using the US and UK weights was 0.98. The correlations of EQ-5D index scores w …
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Fujiwara K, et al. Ann Oncol. 2016 Jun;27(6):1006-1013. doi: 10.1093/annonc/mdw147. Epub 2016 Mar 30. Ann Oncol. 2016. PMID: 27029706 Free article. Clinical Trial.
PATIENTS AND METHODS: HRQoL was assessed with the Functional Assessment of Cancer Therapy-Ovary [FACT-O; comprising FACT-G and the ovarian cancer-specific subscale (OCS)] and EuroQOL EQ-5D instruments before treatment on day 1 of weeks 1, 5, 9, 13, 17, and every 8 weeks th …
PATIENTS AND METHODS: HRQoL was assessed with the Functional Assessment of Cancer Therapy-Ovary [FACT-O; comprising FACT-G and the ovarian c …
Anatomical and refractive outcomes in patients with treated retinopathy of prematurity.
Lolas M, Tuma A, Zanolli M, Agurto R, Stevenson R, Ossandón D. Lolas M, et al. Arch Soc Esp Oftalmol. 2017 Oct;92(10):472-476. doi: 10.1016/j.oftal.2016.12.007. Epub 2017 Jun 16. Arch Soc Esp Oftalmol. 2017. PMID: 28624314 English, Spanish.
The Teller test median was 3.2 cycles/cm (range 0.32-13). There were 16 (22%) cases with a myopic refraction of -6 D or more. The sphere median was -1.75 D (range -16.00 to +3.50 D) and the cylindrical median was 0.00 (range -4.5 to +1.5 D). ...
The Teller test median was 3.2 cycles/cm (range 0.32-13). There were 16 (22%) cases with a myopic refraction of -6 D or more. The sph …
24 results